Member area login
You don't have or don't remember the password!
Click Here
Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

--------------------

ISSN print: 0393 – 0564
ISSN digital: 0392- 7091



BC: Articoli scritti da M. Cicilano

Un caso insolito di mieloma a catene leggere
An uncommon case of light chain multiple myeloma
<p>A 77-year-old patient with a long-lasting stable proteinuria was admitted to the Nephrology Department for the recent onset of nephrotic syndrome and renal failure. The initial laboratory profile was unremarkable, except for a severe hypogammaglobinemia without monoclonal spike on serum protein electrophoresis. Renal biopsy was performed, showing diffuse amyloidosis; however, immunohistochemistry for light chains was negative, leading to the hypothesis of a genetic amyloidosis. To rule out an AL-type amyloidosis, serum immunofixation and FLC measurement were performed, showing a monoclonal component of lambda light chain with a significant impairment of the kappa/lambda ratio. The bone-marrow biopsy led to the final diagnosis of light chain multiple myeloma. A Bortezomib-based chemotherapy regimen was started, however, despite clinical improvement, lambda free light chains showed a marked increase, leading to a Melphalan-based therapeutic strategy. In conclusion, measurement of FLC ratio was crucial for the diagnosis and the therapeutic monitoring in this troublesome myeloma case.</p>
Biochimica Clinica ; 42(1) e12-e14
Casi clinici - Case report